The real – world efficacy and safety of [177Lu]Lu – PSMA-617 for treating PSMA – positive mCRPC

APCCC posted on LinkedIn:

“Initial Experience with [177Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction out on Journal of Nuclear Medicine

The study investigated the real-world efficacy and safety of [177Lu]Lu-PSMA-617, approved for treating prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant Prostate Cancer (mCRPC), at Johns Hopkins Hospital.

Among 76 patients receiving the treatment, a prostate-specific antigen (PSA) response of at least 50% was achieved in 41% of cases, with median PSA progression-free survival (PFS) of 4.1 months and overall survival (OS) of 13.7 months.

Notable adverse effects included grade 3 anemia in 12% and transient xerostomia in 28%. The presence of aggressive-variant prostate cancer genes correlated with shorter PSA PFS. Additionally, artificial intelligence analysis of baseline PSMA PET/CT images identified responders more accurately, suggesting that this approach could enhance patient selection.

The findings indicate promising antitumor activity and a favorable safety profile for [177Lu]Lu-PSMA-617, warranting further validation in larger cohorts.

Initial Experience with [¹⁷⁷Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction

Authors: Andrei Gafita, Andrew Voter, Somya Shesadri, Avery Spitz, Catherine H. Marshall, Steven P. Rowe, Mark C. Markwoski, Martin G. Pomper, A. Cahid Civelek, Michael A. Carducci, Samuel R. Denmeade, Jeffrey Young, Kenneth J. Pienta, Channing J. Paller and Lilja B. Solnes.”

Source: APCCC/Linkedin